Xue, Nina <br/><br/>
Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.  [electronic resource] 

 -  Current cancer drug targets  2014 
 - 671-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5576 
<br/><br/><label>Standard No.: </label>10.2174/1568009614666140908101523  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Body Weight--drug effects<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Drugs, Investigational--administration & dosage<br/>G2 Phase--drug effects<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Isoxazoles--administration & dosage<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice, Nude<br/>Molecular Targeted Therapy--adverse effects<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Pancreatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Pyridones--administration & dosage<br/>Random Allocation<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays